TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01509560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16
Study: NCT04625881

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple derived fiber
Description: This is a combination of soluble and insoluble fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Apple derived fiber
Description: This is a combination of soluble and insoluble fiber
Study: NCT03576963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03046589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation
Study: NCT02123589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep and daily interruption of sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
Study: NCT00154284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Certican)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Certican)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Neoral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Neoral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab (Simulect)
Study: NCT01852539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol 2.0 mg/kg was administrated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway (LMA)
Description: The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
Study: NCT02372201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydro Colon Therapy plus probiotic
Description: Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
Study: NCT02250612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 0.375% SYL040012 (bamosiran)
Study: NCT00154284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect)
Study: NCT03040778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
Study: NCT02256488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT A
Description: Single IM (Intramuscular) administration dose of 0.5 mL of TIVc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT B
Description: Single IM administration dose of 0.5 mL of TIVc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT C
Description: Single IM administration dose of 0.5 mL of TIVc

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVf
Description: Single IM administration dose of 0.5 mL of TIVf
Study: NCT05740371

Intervention type: DRUG
Group type: OTHER
Intervention: Argatroban
Description: Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible.
Study: NCT02502721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20152
Study: NCT03040778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
Study: NCT03714074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK implant abutment
Description: Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia abutment
Description: Imolants will be restored with zirconia abutments and a PEEK superstructure
Study: NCT02250612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 0.750% SYL040012 (bamosiran)
Study: NCT03464331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time exercises
Description: The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxation exercises and deep-breathing exercises
Description: The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
Study: NCT02250612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 1.125% SYL040012 (bamosiran)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 1.5% SYL040012 (bamosiran)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 drop of 0.5 % timolol maleate
Study: NCT00773968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: 120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
Study: NCT03112382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc supplement plus vitamin A and E

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A and E
Study: NCT02492100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modality sexual dysfunction intervention
Study: NCT02430519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Furcation treatment with PRF
Description: PRF Placed into the furcation after flap elevation and debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Furcation Treatment with Allograft and GTR
Description: Allograft and GTR placed into furcation after flap elevation and debridement
Study: NCT03377491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
Study: NCT02430519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich fibrin
Study: NCT02754271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit for Dialysis
Description: A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
Study: NCT00649922

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: 80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 injections Day 1, 1 injection Days 15 and 29
Study: NCT03377491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT01801020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: temperature measuremts
Description: temporal artery temperature measurements will be taken from the forehead
Study: NCT00649922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg adalimumab every other week
Study: NCT03223415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection and isolation of C. difficile carriers
Description: Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward.
Study: NCT02954133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (7 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (7 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (5 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
Study: NCT01801020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: temperature measuremts
Description: different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
Study: NCT03902704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleverscope
Description: the device is used in patients without difficult airways predictors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope / Videolaryngoscope C-MAC® Storz
Description: the device is used in patients with difficult airways predictors
Study: NCT02274714

Intervention type: OTHER
Intervention: Questionnaire Only
Description: Subjects will have an interview with a study coordinator to fill out questionnaires for the study

Intervention type: OTHER
Intervention: Questionnaire Only
Description: Subjects will have an interview with a study coordinator to fill out questionnaires for the study
Study: NCT04293146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre-pectoral IBBR
Description: The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sub-pectoral IBBR
Description: The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
Study: NCT00668122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Ciprofloxacin XR 1000 mg orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro IR (Ciprofloxacin, BAYQ3939)
Description: Ciprofloxacin IR 500 mg orally twice a day
Study: NCT02925455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally-controlled functional electrical stimulation
Description: Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand therapy video games
Description: Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand therapy video games
Description: Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
Study: NCT03484975

Intervention type: DEVICE
Group type: OTHER
Intervention: Observation group
Description: Collect coronary images with a hybrid IVUS OCT system.
Study: NCT01843426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan
Description: An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
Study: NCT04593472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Healthcare Wishes in Primary Care (SHARE)
Description: SHARE is a multicomponent communication intervention to proactively engage family members or friends to support advance care planning in primary care.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimally Enhanced Usual Care
Description: Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive.
Study: NCT04477642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 10mg/kg intravenously administered on Day 1
Study: NCT02403726

Intervention type: PROCEDURE
Intervention: Operation
Description: Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.

Intervention type: PROCEDURE
Intervention: Non-operative treatment
Description: Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
Study: NCT01754662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavones
Description: 2 bars daily for 8 weeks.
Study: NCT02954133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
Study: NCT01754662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavones
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: 2 bars daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: 2 bars daily for 8 weeks.
Study: NCT02954133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (3.5 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
Study: NCT01754662

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03093922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2